Unavailability of Branded Drugs with Desired Active Ingredients to Fuel Animal Drug Compounding Market Growth, Set for US$ 4 Bn by 2030
Share this article Share this article NEW YORK, Feb. 3, 2021 /PRNewswire/ -- In order to provide medical therapy suitable for individual animal needs, compounded drugs are available, containing the desired active ingredients. For instance, currently, no FDA approved drug is available in the market for the treatment of megacolon (constipation) in cats. In 2000, Cisapride, the only safe and effective therapy for the treatment of chronic constipation in cats was removed from the U.S. human market. Hence, compounding remains the only choice for veterans to provide cisapride for animals in need of...
Source: prnewswire.com